Basic Research
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2006; 12(30): 4843-4849
Published online Aug 14, 2006. doi: 10.3748/wjg.v12.i30.4843
Figure 1
Figure 1 Northern blot of human pancreatic carcinoma cell lines utilizing a cDNA probe for tissue factor (TF) and a ribosomal cDNA control probe (S138). Cell culture conditions with and without (ø) fetal calf serum (FCS).
Figure 2
Figure 2 Assessment of TF and asTF expression by RT-PCR. 1: DLD-1; 2: SW48; 3: PANC-1; 4: BxPC-3; 5: PaCa-44; 6: Capan-2; 7: Capan-1; 8: AsPC-1; 9: NP9; 10: NP29; 11: HeLa; 12: Fibroblasts; 13: Negative control.
Figure 3
Figure 3 Representative demonstration of tissue factor (TF) expression by immunofluorescence in AsPC-1 (A) and CAPAN-1 (B) pancreatic cancer cell lines, in tissue of pancreatic cancer (C) and chronic pancreatitis (D).
Figure 4
Figure 4 Plasma concentrations of tissue factor (TF) in patients with pancreatic cancer (PCa) versus controls (Co). Bars indicate means and standard deviation.
Figure 5
Figure 5 Plasma concentrations of thrombin-antithrombin complex (TAT) in patients with pancreatic cancer (PCa), chronic pancreatitis (CP) and healthy controls (Co). Bars indicate means and standard deviation.
Figure 6
Figure 6 Plasma concentrations of prothrombin fragment 1 + 2 (F1 + 2) in patients with pancreatic cancer (PCa), chronic pancreatitis (CP) and healthy controls (Co). Bars indicate means and standard deviation.